Geht es nach Okay der FDA jetzt Richtung Norden ?

[winston-wolfe]

Acadia Healthcare Company, Inc. (ACHC Quick QuoteACHC - Free Report) is well positioned for growth on the back of improving patient volumes, admissions, commercial business and growing demand for behavioral health and substance use treatments.

The company is actively bolstering its capabilities to address the increasing demand in these critical areas.
...
https://www.zacks.com/stock/news/2251328/compelling-reasons-…

[winston-wolfe]

Acadia Pharmaceuticals surges 32% after win in patent suit over Nuplazid

Acadia Pharmaceuticals (NASDAQ:ACAD) jumped 32% after winning summary judgement in a patent suit regarding its drug Nuplazid, which is used to treat Parkinson's disease. Acadia won the judgement against generic maker MSN Laboratories.

"For the foregoing reasons, the Court grants summary judgement to Acadia," U.S. Disctrict Court Judge Gregory B. Williams wrote in a court opinion on Wednesday.

Acadia (ACAD) filed separate lawsuits last October alleging that copies of Nuplazid infringed a patent, including a lawsuit against MSN Laboratories.
...
https://seekingalpha.com/news/4045975-acadia-pharmaceuticals…

[winston-wolfe]

Why Acadia Pharmaceuticals Stock Is Rising Today

An analyst upgrade is sparking a rally in the drugmaker's shares today.
What happened
Acadia Pharmaceuticals (ACAD 7.73%) is having a strong session Tuesday. Specifically, the drugmaker's shares were up by a healthy 6.7% on moderate volume at 10:02 a.m. ET.

What's sparking this rally? Ahead of the opening bell, JPMorgan analyst Tessa Romero upgraded the bank's outlook from neutral to overweight and raised its 12-month price target on the stock to $32 per share (up from $29 per share). This updated price target implies a noteworthy 47% upside potential relative to Acadia Pharmaceuticals' closing price on Monday.
...
https://www.fool.com/investing/2023/10/10/why-acadia-pharmac…

[winston-wolfe]

Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up

Acadia Pharmaceuticals Inc. (ACAD Quick QuoteACAD - Free Report) reported second-quarter 2023 earnings of 1 cent per share. The Zacks Consensus Estimate was pegged at a loss of 12 cents per share. In the year-ago quarter, the company had incurred a loss of 21 cents per share.

The company recorded net product revenues of $165.2 million in the reported quarter, surpassing the Zacks Consensus Estimate of $154 million. Acadia’s net product revenues comprised of revenues from two of its marketed products, such as Nuplazid (pimavanserin) and the newly-approved Daybue (trofinetide).
...
https://www.zacks.com/stock/news/2131843/acadia-acad-q2-earn…

[winston-wolfe]

Why Acadia Pharmaceuticals Stock Is Soaring Today

Shares of Acadia Pharmaceuticals (ACAD 3.99%) were soaring 18.3% higher as of 11:03 a.m. ET on Friday. The big jump came after the drugmaker announced on Thursday that it has acquired expanded rights to two drugs.

Acadia signed an agreement with Neuren Pharmaceuticals to pick up rights to trofinetide outside of North America. It launched the drug under the brand name Daybue in the U.S. earlier this year as a treatment for Rett syndrome, a rare genetic neurological disorder.

The company also acquired global rights for Neuren's NNZ-2591. This experimental drug is being evaluated in clinical trials targeting Rett syndrome and Fragile X syndrome, another rare genetic disorder.

In addition, Acadia provided an update giving a sneak peek at its second-quarter revenue. The company expects to report second-quarter net sales of Daybue of between $21 million and $23 million and net sales of Parkinson's disease psychosis drug Nuplazid of between $140 million and $144 million.

Acadia looks for third-quarter sales of Daybue in the range of $45 million to $55 million. It projects full-year sales of Nuplazid will be between $530 million and $545 million.
...
https://www.fool.com/investing/2023/07/14/why-acadia-pharmac…

[winston-wolfe]

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

SAN DIEGO–(BUSINESS WIRE)–Mar. 10, 2023– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the first and only drug approved for the treatment of Rett syndrome.
...
https://acadia.com/media/news-releases/acadia-pharmaceutical…

[winston-wolfe]

Acadia Pharmaceuticals upgraded to buy at Wainwright on trofinetide potential

H.C. Wainwright has upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to buy from neutral on the potential of trofinetide to take market share for Rett syndrome.
The firm has doubled its price target of $36 (34% upside based on Wednesday's close).
The target assumes estimated revenue of $1.8B from Nuplazid (pimavanserin) and trofinetide in 2030.
Analyst Andrew Fein said that after calls with pediatric neurologists with expertise in Rett syndrome, he thinks trofinetide can gain significant market share barring any other disease-modifying treatments.
"Along with trofinetide, we think the recently announced collaboration deal with Stoke Therapeutics (STOK -1.3%) for SYNGAP1 and MECP2, in particular, might help boost Acadia's pipeline in the future," he added.

[sedar]

Antwort auf Beitrag Nr.: 70.307.906 von Malecon am 23.12.21 13:50:01

überbewertet

ich schreib das doch nicht wegen dir oder mische mich da ein...wegen dir

du interessierst mich dahingegen keinen meter

er hat mich angesprochen ...was bildest du dir eigentlich ein

ich hab dir mal eine persönliche mail wegen evfm und ptn geschrieben....nach deiner antwort hab ich mich ganz klar erklärt
und damit fertig..

die hauptaussage hier war nur....egal was einer schreibt...man ist für sein tun selbst verantwortlich...und jetzt ist es gut

setz dich weiter mit bkn oder wie dieser user heisst auseinander....mir ist die zeit zuschaue

[Malecon]

Ich meine mit "lass ihn", dass wenn der User Tzingtau böswillig Falschbeschuldigungen über mich verbreitet, dann ist das eine juristische Angelegenheit zwischen ihm und mir, du musst dich da als Dritter nicht einmischen.

[sedar]

lass ihn....

das entscheidest nicht du


ich schreib nicht oft , aber wenn ich es mache , dann hat es für Mich einen sinn

frohe tage